NO952261L - Antacidiumforbindelser og fremgangsmåte for fremstilling derav - Google Patents

Antacidiumforbindelser og fremgangsmåte for fremstilling derav

Info

Publication number
NO952261L
NO952261L NO952261A NO952261A NO952261L NO 952261 L NO952261 L NO 952261L NO 952261 A NO952261 A NO 952261A NO 952261 A NO952261 A NO 952261A NO 952261 L NO952261 L NO 952261L
Authority
NO
Norway
Prior art keywords
antacidium
compounds
preparation
methods
composition
Prior art date
Application number
NO952261A
Other languages
English (en)
Other versions
NO952261D0 (no
Inventor
Gary G Liversidge
Gregory L Mcintire
Original Assignee
Eastman Kodak Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastman Kodak Co filed Critical Eastman Kodak Co
Publication of NO952261L publication Critical patent/NO952261L/no
Publication of NO952261D0 publication Critical patent/NO952261D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Antacld sammensetning som omfatter partikler bestående vesentlig av et alumlnlum-basert nøytrallserlngsmiddel som har en gjennomsnittlig partlkkelstørrelse som er mindre enn omtrent 3 mikroner og en fremgangsmåte for fremstilling av sammensetningen er beskrevet. Disse sammensetningene utviser betydelig forsterkede nøytrallseringsrater 1 forhold til sammensetninger som Inneholder større partikler og er nyttige for be-handling av pattedyr med smerter assosiert med sur mave.
NO952261A 1992-12-11 1995-06-08 Antacidiumforbindelser og fremgangsmåte for fremstilling derav NO952261D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98929692A 1992-12-11 1992-12-11
PCT/US1993/011720 WO1994013304A2 (en) 1992-12-11 1993-12-03 Antacid composition and method of production

Publications (2)

Publication Number Publication Date
NO952261L true NO952261L (no) 1995-06-08
NO952261D0 NO952261D0 (no) 1995-06-08

Family

ID=25534976

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952261A NO952261D0 (no) 1992-12-11 1995-06-08 Antacidiumforbindelser og fremgangsmåte for fremstilling derav

Country Status (10)

Country Link
EP (1) EP0673253A1 (no)
JP (1) JPH08504442A (no)
KR (1) KR950703982A (no)
AU (1) AU6390894A (no)
CA (1) CA2150383A1 (no)
CZ (1) CZ148695A3 (no)
FI (1) FI952859A (no)
NO (1) NO952261D0 (no)
SK (1) SK76595A3 (no)
WO (1) WO1994013304A2 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69413544T2 (de) * 1993-08-24 1999-05-27 Kappa Pharmaceuticals Ltd., Reading Reduzierte absorption von fettsäuren
DE69535669T2 (de) 1994-05-09 2008-12-04 Oxford Biomedica (Uk) Ltd. Retrovirale vektoren mit verminderter rekombinationsrate
US5874112A (en) * 1997-03-31 1999-02-23 Mcneil Ppc-Inc. Translucent antacid suspension
AU2002951438A0 (en) * 2002-09-17 2002-10-03 Nauveau Technology Investments Ltd Methods and compositions for treatment of excess stomach acid in mammals
RU2013148719A (ru) * 2013-10-31 2015-05-10 Геннадий Гильфанович Галимов Композиция на основе гидроксоалюмината хлорида магния, содержащая гидроксид магния, в качестве терапевтического препарата
WO2016104367A1 (ja) * 2014-12-22 2016-06-30 株式会社Ｌｔｔバイオファーマ 機能性ディスペプシア治療薬

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843778A (en) * 1970-04-28 1974-10-22 Rorer Inc William H Antacids
US4271142A (en) * 1979-06-18 1981-06-02 Life Savers, Inc. Portable liquid antacids
FR2512344A1 (fr) * 1981-09-08 1983-03-11 Af Aplicaciones Far Lab Procede de fabrication d'une suspension stable d'hydroxyde d'alumine et/ou d'hydroxyde de magnesie comme agent actif des antacida

Also Published As

Publication number Publication date
WO1994013304A3 (en) 1994-09-01
EP0673253A1 (en) 1995-09-27
JPH08504442A (ja) 1996-05-14
CA2150383A1 (en) 1994-06-23
FI952859A0 (fi) 1995-06-09
CZ148695A3 (en) 1995-12-13
KR950703982A (ko) 1995-11-17
AU6390894A (en) 1994-07-04
WO1994013304A2 (en) 1994-06-23
SK76595A3 (en) 1997-01-08
FI952859A (fi) 1995-06-09
NO952261D0 (no) 1995-06-08

Similar Documents

Publication Publication Date Title
FR2450608A1 (fr) Agent carcinostatique et immunostimulant contenant un lysophospholipide et un phospholipide et procede pour le preparer
MX9603831A (es) Agentes antitromboticos.
MX9605650A (es) Formulaciones de propionato de fluticasona.
MX163955B (es) Composicion farmaceutica de dihidrocodeina e ibuprofen
CA2094267A1 (fr) Utilisation de compositions a base d'alcools gras, pour la preparation d'emulsions; procede de preparation d'emulsions et emulsions ainsi obtenues
IL106640A (en) Pharmaceutical compositions for the treatment and prevention of irritable bowel syndrome
HK1005241A1 (en) Cell adhesion inhibitors
NO308792B1 (no) Derivater av valproinsyre og 2-valproensyreamider, farmasøytisk sammensetning derav og deres anvendelse for fremstilling av et farmasøytisk preparat
ZA948669B (en) New pyrazine carboxamide derivatives the preparation thereof and their use in pharmaceutical compositions
CA2108903A1 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
HK1030604A1 (en) Method for the synthesis of huperzine a and analogs thereof and compounds useful therein
NO952261L (no) Antacidiumforbindelser og fremgangsmåte for fremstilling derav
IT1240473B (it) Procedimento per migliorare l'efficacia terapeutica di corticosteroidi liposolubili e composizione per l'attuazione di tale procedimento
IL105090A0 (en) Compositions of n-(phosphonoacetyl)-l-aspartic acid and methods of their use as broad spectrum antivirals
DE69433012D1 (de) Verfahren zur herstellung von oralen dosierungsformulierungen enthaltend diclofenac
IL124431A0 (en) Sulfur containing dl-tert-butylphenol compounds useful as anti-inflammatory agents
BG103632A (en) Pharmaceutical compositions containing ibuprophene and domperidon for migraine treatment
ZA872693B (en) Thiodiazolylurea-containing agent for defoliating plants
EP0135189A3 (en) Pharmaceutically useful malonamides
PT74931B (en) Process for preparing n-(aryloxyalkyl)-n'-(aminoalkyl) ureas and of pharmaceutical compositions containing the same
FR2604903B1 (fr) Agents therapeutiques sous forme de particules submicroscopiques contre des parasitoses et compositions pharmaceutiques les contenant
NZ509881A (en) Micronised pharmaceutical compositions containing colistin sulphomethate sodium
JPS57181020A (en) Poultice base composition
EP0154886A3 (de) Carboxyalkyldipeptidderivate, Verfahren zu deren Herstellung, diese enthaltende Mittel und deren Verwendung
JPS57156436A (en) Angelic ester derivative and perfume composition comprising it